Abstract 784P
Background
Choriocarcinoma (CC) is a rare and highly aggressive cancer that exists in both the gestational (GCC) and non-gestational (NGCC) forms. Our research focused on comparing clinical outcomes, response to therapy, and prognostic determinants between these subtypes.
Methods
We analyzed data from the SEER database of patients diagnosed with CC between 2000 and 2020. Patients who were not diagnosed based on histology, previous history of cancer or other concurrent malignancies, or unknown data were excluded. The chi-square test were used for clinical features comparison. Kaplan-Meier estimation, log-rank tests, and Cox regression analyses were used to identify prognostic factors for overall survival (OS) and cancer specific survival (CSS). A nomogram was developed to predict 5-year OS, and a calibration curve was plotted to evaluate the agreement between the actual (observed) outcomes and expected probabilities.
Results
Of the 719 patients studied, 520 had GCC, and 200 had NGCC. Younger individuals were more common in the GCC. Additionally, a higher percentage of patients with NGCC were married (63.0% vs. 52.6%). AJCC stage distribution also differed; 47.4% of GCC patients were at stage I compared to 6.0% of NGCC patients. The surgery rates were higher in the NGCC group (79.5% vs. 60.9%). Patients with GCC had better OS than those with NGCC (93% vs. 71.2%, p = 0.001). CSS rates were 66.8% for NGCC and 65.2% for GCC (p = 0.001).
We developed a prognostic nomogram that integrated significant variables from multivariate analysis. For GCC, the model assigned the highest weight to radiation, followed by metastasis, and marital status. The AUC was 0.711 (95% CI: 0.64–0.79), and the calibration curves exhibited a mean error of 0.015. The NGCC model assigned the highest weights to metastasis, chemotherapy, and age. The AUC was 0.837 (95% CI, 0.77–0.9), and the calibration curve for 5-year survival demonstrated a mean error of 0.01.
Conclusions
Our study highlights the significant clinical and survival differences between GCC and NGCC patients. We developed prognostic nomograms tailored to each subtype to enhance prediction and support personalized management.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
782P - Predicting survival in malignant struma ovarii (MSO): A machine learning approach
Presenter: Sakhr Alshwayyat
Session: Poster session 02
Resources:
Abstract
783P - ESCAT gene actionability detection in early-stage ovarian: A descriptive analysis of an Italian referral center
Presenter: Floriana Camarda
Session: Poster session 02
785P - Online prognostic calculator for gestational trophoblastic neoplasia (GTN): A tool for personalized treatment planning
Presenter: Zena Haddadin
Session: Poster session 02
786P - Exploring risk factors for recurrence in stage I uterine leiomyosarcomas: Is there a subgroup with a favorable prognosis?
Presenter: Alejandro Gallego
Session: Poster session 02
787P - First-in-human, phase I study of CBP-1008, a first-in-class bi-specific ligand drug conjugate (Bi-XDC), in patients with advanced solid tumors
Presenter: Ning Li
Session: Poster session 02
788P - Pembrolizumab plus lenvatinib (PL) in recurrent clear cell gynecological cancer (CCGC): Phase II LARA trial (GCGS-OV4/ APGOT-OV3)
Presenter: Natalie Ngoi
Session: Poster session 02
789P - Translational study and preliminary clinical trial of WX390 monotherapy in cancers with concurrence of PIK3CA and ARID1A mutations
Presenter: Jiajia Li
Session: Poster session 02
790P - The landscape of human epidermal growth factor receptor 2 (HER2) expression in gynecologic tumors (GTs)
Presenter: Carmen Garcia Duran
Session: Poster session 02
791P - Activity of ERK1/2 inhibitor ASTX029 in patients with gynecological malignancies harboring genomic alterations in the MAPK pathway
Presenter: Geoffrey Shapiro
Session: Poster session 02
792P - The differences in immunogenicity of TP53 mutated endometrial-, high-grade serous ovarian- and triple negative breast carcinomas
Presenter: Alain Zeimet
Session: Poster session 02